2 weeks Ago By ABMN Staff
Shares of Natera, Inc. ( NASDAQ:NTRA – Get Free Report ) have received an average recommendation of “Buy” from the sixteen research firms that are covering the company, MarketBeat.com reports.
Sixteen equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued a report on the stock in the last year is $125.69.
A number of brokerages have commented on NTRA. The Goldman Sachs Group lifted their price objective on shares of Natera from $125.00 to $140.
00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Leerink Partners upped their price objective on Natera from $140.00 to $150.
00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird lifted their target price on Natera from $117.
00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. BTIG Research boosted their target price on Natera from $125.
00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, UBS Group lowered their price target on Natera from $160.
00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Check Out Our Latest Stock Analysis on Natera Natera Stock Down 0.
1 % Insider Transactions at Natera In related news, insider Solomon Moshkevich sold 1,196 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $118.21, for a total value of $141,379.
16. Following the completion of the sale, the insider now owns 110,695 shares in the company, valued at approximately $13,085,255.95.
The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website .
In other Natera news, insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.
16. Following the transaction, the insider now owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95.
This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink .
Also, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $126.45, for a total transaction of $235,955.
70. Following the completion of the sale, the chief financial officer now owns 68,851 shares of the company’s stock, valued at approximately $8,706,208.95.
This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here .
Over the last three months, insiders have sold 47,464 shares of company stock valued at $5,849,977. 7.60% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows Institutional investors and hedge funds have recently made changes to their positions in the stock. Itau Unibanco Holding S.A.
purchased a new position in shares of Natera in the 2nd quarter worth approximately $28,000. Quarry LP boosted its stake in Natera by 148.4% in the second quarter.
Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares in the last quarter. GAMMA Investing LLC boosted its stake in Natera by 50.0% in the second quarter.
GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares in the last quarter. Covestor Ltd grew its holdings in Natera by 34.3% in the third quarter.
Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the last quarter. Finally, Tobam purchased a new stake in shares of Natera during the 2nd quarter valued at $74,000. 99.
90% of the stock is currently owned by hedge funds and other institutional investors. Natera Company Profile ( Get Free Report Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter ..
